Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Only 2 subjects who tested negatively for HCV RNA in the liver at the end of treatment relapsed after discontinuing IFN therapy. 7557858

1995

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE The polymerase chain reaction (PCR) was used to examine expression of interferon-alpha (IFN A) genes in general and the expression of messenger RNA (mRNA) encoding the subtypes IFN-alpha-2 and IFN-alpha-4 in blood and liver biopsy samples from patients with chronic hepatitis C or hepatitis non-A, non-B (HC/HNANB) infection entered into a trial of IFN-alpha-2a therapy. 7948820

1994

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE To determine whether sequence variations of the HCV NS5B region correlate with response to IFN therapy, pretreatment serum samples from 40 patients with chronic HCV infection who were subsequently treated with IFN (> or = 3 MU thrice weekly for 24 weeks) and had well-characterized biochemical responses were studied. 8732174

1995

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Quantification of viral genomes during acute and chronic HCV infection seem to be of major importance to predict the response rat to IFN. 8836886

1996

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE A region associated with sensitivity to IFN has been identified in subtype HCV-1b isolates from Japanese patients in the carboxyterminal half of the nonstructural protein NS5A (between codon 2209 and 2248). 9049228

1997

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE A sustained complete response to IFN therapy occurred in none of the ten patients with the wild-type HCV-1b who had an NS5A2209-2248 sequence identical to the prototype HCV-1b and in none of the six patients with the intermediate-type HCV-1b that had 1 mutation. 9049230

1997

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Seven children with the HCV genotype II resistant to IFN, including 8 weeks of IFN-beta administration, and showed no significant reduction in HCV core antibody titre. 9296534

1997

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE In addition, a greater percentage of patients infected with HCV genotype 1 treated with 9 microg CIFN had undetectable HCV RNA concentrations when compared with patients in the 15-microg IFN-alpha2b cohort at the end of treatment (24% vs. 15%; P = .04). 9303508

1997

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The findings suggest that measuring HCV RNA in serum before and soon after beginning treatment can be helpful for selecting patients who are most likely to have a sustained complete response to standard schedule of alpha-IFN and for identifying patients in whom alternative strategies should be examined. 9496364

1998

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE Expression of the IFN receptor in hepatocytes may be directly associated with a hepatitis C virus (HCV) infection and the response to IFN therapy. 9783688

1998

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE When the above factors were used to construct a predictive model to determine response to retreatment, it was found that the absence of a 2 log10 drop in HCV RNA concentrations during the first course of IFN therapy was the most reliable indicator of non-response to retreatment (likelihood ratio = 10, P = 0.0014). 9795916

1998

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE Hepatitis C virus (HCV) infection is remarkable by its ability to evade host antiviral defenses; however, there is little information as to whether endogenous IFN is activated or not in this disease. 10347136

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE At biochemical and virological long-term follow-up performed in 26 sustained virological responders 3.5-8.8 years (mean +/- SD, 5.4+/-1.6 years) after the end of IFN therapy, 22 patients (85%) had normal serum ALT levels, and 24 patients (92%) were HCV RNA negative in serum. 10365802

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE We used single-strand conformation polymorphism analysis combined with cloning and sequencing strategies to characterize the genetic evolution of HCV second envelope gene hypervariable region 1 (HVR1) quasispecies during and after IFN therapy in patients who failed to clear HCV RNA. 10400744

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE It is concluded that expression of IFN receptor genes in the liver is a useful index for predicting the short- and long-term efficacy of IFN therapy in patients with chronic HCV infection. 10421402

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Fifteen nonresponder patients with HCV-1 (4 patients with HCV-1a and 11 patients with HCV-1b) infection were studied while being retreated for 2 months (phase 1) with IFN-alpha (6 MU given three times a week), followed by IFN plus ribavirin or IFN alone for an additional 6 months (phase 2). 10438811

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE These IFN-resistant HCVs were already present before therapy as minor quasispecies and were selected by IFN in nonresponders. 10479124

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE As with Japanese HCV patients with genotypes 1b/II-2b/IV, higher hepatic IFNAR mRNA expression in the United States with predominant genotypes 1a/I and 1b/II appears to correlate with response to IFN therapy and a low HCV RNA titer but not with the total HAI or its components. 10505743

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Treatment and retreatment with IFN was associated in our non-responder patients with evolution of the ISDR quasispecies towards a rather homogeneous viral population carrying a conserved or minimally mutated ISDR motif, supporting the idea that this motif may be relevant for IFN resistance in HCV 1b-infected individuals. 10607252

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Prospective studies on the long-term natural history of HCV infection in this setting are needed and well designed randomized controlled trials are necessary to determine whether these patients would benefit from IFN or a combination treatment with ribavirin regimen. 10622586

1999

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE We quantified hepatitis C virus (HCV) RNA at different times in plasma and peripheral blood mononuclear cells (PBMC) in 51 patients with chronic hepatitis C undergoing interferon-alpha2a (IFN-alpha2a) therapy. 10695632

2000

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The hepatitis C virus infection is highly dynamic and a daily high dose of IFN may induce a decline of viremia of 95+/-10% of baseline value after 24 to 48 hours of treatment. 10797610

2000

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Patients with hepatitis C virus (HCV) genotype 1 are more resistant to treatment with IFN, whereas low viral load at baseline and a marked decline in the HCV RNA level during the first 2-12 weeks of IFN therapy are associated with enhanced treatment efficacy. 10886533

2000

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. 11099064

2000

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Intrahepatic mRNA levels of type-I interferon (IFN) receptor genes have been shown to correlate with the clinical efficacy of IFN therapy in patients with chronic hepatitis C. Recently, co-infection by serologically-silent hepatitis B virus (HBV) has been assumed to be associated with the poor IFN response in patients with chronic hepatitis C. The aim of this study was to investigate the relationship between the co-infection of serologically-silent HBV and type-I IFN receptor gene expression in the liver of patients with chronic hepatitis C. The intrahepatic mRNA levels of IFNAR2, one of the two subunits of the type-I IFN receptor, were quantified and compared with both the prevalence of HBV DNA and the hepatitis C virus (HCV) genotype in 45 patients with chronic hepatitis C, who were negative for hepatitis B surface antigen. 11170061

2001